Rick E Winningham has served as Chief Executive Officer and Chairman of the Board of Directors of Theravance Biopharma since its spin-off from Theravance, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Theravance, Inc. Prior to joining Theravance, Inc., he served as President, Bristol-Myers Squibb (BMS) Oncology/Immunology/Oncology Therapeutics Network (OTN) from 1997 to 2001, and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen-year period with BMS and its predecessor, Bristol-Myers, Mr. Winningham held various U.S. and global management positions. During his tenure with BMS, he was associated with the development and commercialization of several major pharmaceutical products, such as Taxol®, Paraplatin®, Zerit®, Videx®, Reyataz®, and Abilify®.
Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. from Southern Illinois University. He is the Chairman of the Board of Directors of Theravance, Inc. and California Healthcare Institute (CHI) and a member of the Board of Directors of Jazz Pharmaceuticals. Mr. Winningham is also a member of Biotechnology Industry Organization’s Board of Directors, serving on the Health Section Governing Board and Board Standing Committee on Reimbursement.
Leonard M. Blum joined Theravance Biopharma as Senior Vice President and Chief Commercial Officer in October 2014. Prior to joining Theravance Biopharma, Mr. Blum served as Senior Vice President and Chief Commercial Officer of Theravance, Inc. since July 2007. From 2000-2007, Mr. Blum headed the commercial function at ICOS Corporation, serving as Senior Vice President of Sales and Marketing from 2004 until the company's acquisition by Eli Lilly and Co. From 1987-2000, Mr. Blum held positions of increasing responsibility in marketing and sales management at Merck & Co. in both U.S. and international markets. Mr. Blum earned an M.B.A. from Stanford University, studied Finance as a Fulbright Fellow at the University of Zurich, and received an A.B. in Economics, magna cum laude, from Princeton University. Mr. Blum served as an officer in the U.S. Army Special Forces.
Renee Gala is the Senior Vice President of Finance and Principal Financial Officer of Theravance Biopharma. She joined the company in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance in June 2006, where she held various roles in the finance organization before being promoted to Vice President of Finance in January 2013. From 2001 to 2006, Ms. Gala worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development. Prior to joining Eli Lilly, she spent seven years in the energy industry in the United States and internationally in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Gala earned a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.
Jeffrey D. Jonker joined Theravance Biopharma as Senior Vice President, Corporate and Business Development in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance as Senior Vice President, Corporate Business Development in October 2013. Prior to joining Theravance, Mr. Jonker served as Chief Business Officer of Satori Pharmaceuticals. Previously, he held senior business development and corporate strategy positions with Gloucester Pharmaceuticals and Genentech, Inc. Prior to Genentech, Mr. Jonker was an attorney in the Technology Transactions Group of Wilson, Sonsini, Goodrich & Rosati, representing clients in biotech, life sciences and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.
Junning Lee, Ph.D., joined Theravance Biopharma as Senior Vice President, Technical Operations in September 2014. Prior to joining Theravance Biopharma, he served as Senior Vice President, Technical Operations of Theravance, Inc. since January 2014 and held various positions in the Technical Operations Department since 2001. Prior to that, Dr. Lee had more than 11 years of increasing responsibility at Schering-Plough Research Institute. He was an NIH Postdoctoral Fellow at Oregon State University. He received his Ph.D. in Organic Chemistry from Boston University, and obtained a BS Pharmacy from China Pharmaceutical University, Nanjing, China, where he graduated with University Honors.
Mathai Mammen, M.D., Ph.D., joined Theravance Biopharma as Senior Vice President, Research and Development, in October 2014. Prior to joining Theravance Biopharma, he co-founded Theravance, Inc. in 1996 and held senior management positions from 2008 to 2014, most recently as Senior Vice President, Research and Development. Previously, he served in various positions in both the Medicinal Chemistry Department and the Molecular and Cellular Biology Departments at Theravance, Inc., most recently as Vice President, Molecular and Cellular Biology. Dr. Mammen obtained his M.D. from Harvard Medical School/Massachusetts Institute of Technology, and his Ph.D. in Physical Organic Chemistry from Harvard University's Department of Chemistry working with George Whitesides, Ph.D. Dr. Mammen obtained his Bachelor's Degree in Chemistry from Dalhousie University in Halifax, Nova Scotia.
Frank Pasqualone joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance, Inc. as Senior Vice President, Operations in January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol-Myers Squibb (BMS). Over a 25-year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.
Bradford J. Shafer joined Theravance Biopharma as Senior Vice President and General Counsel in September 2014. Prior to joining Theravance Biopharma, he served as Senior Vice President, General Counsel and Secretary of Theravance, Inc. since August 1999. From 1996 to 1999, Mr. Shafer served as General Counsel of Heartport, Inc., a cardiovascular medical device company. From 1993 to 1996 Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor-in-Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude.
Dennis O. Driver joined Theravance Biopharma as Vice President, Human Resources in September 2014. Prior to joining Theravance Biopharma, Mr. Driver served as Vice President, Human Resources of Theravance, Inc. since October 2007. From 2001 through 2007, Mr. Driver served as Vice President, Human Resources at various companies within the Johnson & Johnson family of businesses including Biosense Webster, Inc., Scios Inc. and Cordis Corporation. Prior to that, he held senior level human resources leadership positions with PeopleSoft, Silicon Graphics, Inc. and Acuson Corporation. He has a wealth of human resources expertise in both domestic and international operations. Mr. Driver holds a B.A. in Business Administration from Stillman College, where he graduated summa cum laude. Mr. Driver served as an officer in the United States Marine Corps.
Brett K. Haumann joined Theravance Biopharma as Vice President, Clinical Development and Operations in June 2014 in connection with the spin-off from Theravance, Inc., after joining Theravance as Vice President, Clinical Development in October 2013. Prior to joining Theravance, Dr. Haumann served as Chief Medical Officer at Circassia Limited. Previously, Dr. Haumann held senior positions at GlaxoSmithKline, including Medicines Development Leader and Vice President Clinical Development. Dr. Haumann has more than 15 years of experience in the discovery and development of pulmonary and allergy medicines. Dr. Haumann completed his M.D. at the University of Witwatersrand Medical School, South Africa and holds an M.B.A. from Open University, United Kingdom.